Septerna

Septerna, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the identification and advancement of orally administered, small molecule therapies that modulate G protein-coupled receptors (GPCRs). The company's pipeline is designed to address a spectrum of conditions within endocrinology, immunology and inflammation, and metabolic disorders. Among its key programs, Septerna is developing SEP-786, an oral small molecule serving as a PTH1R agonist for individuals suffering from hypoparathyroidism. Another candidate, SEP-631, is an oral small molecule MRGPRX2 NAM aimed at treating chronic spontaneous urticaria and other mast cell-related ailments. Furthermore, its TSHR Program involves an oral small molecule TSHR NAM for both Graves' disease and thyroid eye disease. The company is also progressing oral small molecule single- and multi-incretin receptor agonists to tackle metabolic issues such as obesity and type 2 diabetes. Founded in 2019, Septerna, Inc. is headquartered in South San Francisco, California. It was formerly known as GPCR NewCo, Inc. until its rebranding to Septerna Inc. in June 2021.